NIP
TGTX icon

Nicholas Investment Partners’s TG Therapeutics TGTX Stock Holding History

Nicholas Investment Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-146,941
Closed -$5.29M – 236
2025
Q2 		$5.29M Buy
146,941
+37,202
+34% +$1.39M 0.47% 85
2025
Q1 		$4.33M Buy
109,739
+25,592
+30% +$861K 0.45% 94
2024
Q4 		$2.53M Sell
84,147
-25,559
-23% -$734K 0.22% 143
2024
Q3 		$2.57M Buy
+109,706
New +$2.4M 0.24% 149
2022
Q2 		– Sell
-129,050
Closed -$1.23M – 205
2022
Q1 		$1.23M Sell
129,050
-156,759
-55% -$1.81M 0.09% 163
2021
Q4 		$5.43M Sell
285,809
-200,029
-41% -$5.19M 0.34% 105
2021
Q3 		$16.2M Sell
485,838
-175,126
-26% -$5.42M 1.18% 16
2021
Q2 		$25.6M Buy
660,964
+35,177
+6% +$1.38M 1.61% 4
2021
Q1 		$30.2M Sell
625,787
-2,385
-0.4% -$115K 2.1% 1
2020
Q4 		$32.7M Buy
628,172
+398,720
+174% +$13.5M 2.52% 1
2020
Q3 		$6.14M Buy
+229,452
New +$5.28M 0.66% 53

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nicholas Investment Partners's TGTX Position: Q3 2025 in Review

Nicholas Investment Partners sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 146,941 shares — an estimated $5.29M sold.

Nicholas Investment Partners first reported a position in TGTX in Q3 2020 and held it in 11 quarters. The position peaked at $32.7M in Q4 2020. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Nicholas Investment Partners reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 146,941 TG Therapeutics shares in Q3 2025, an estimated $5.29M.
  • Nicholas Investment Partners first reported a position in TG Therapeutics in Q3 2020 and held it in 11 quarters.
  • Nicholas Investment Partners's TG Therapeutics position peaked at $32.7M in Q4 2020.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Nicholas Investment Partners's 13F filing for Q3 2025, filed 14 Nov 2025.